We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Automated Microscopy Compared for Routine Malaria Diagnosis

By LabMedica International staff writers
Posted on 10 Oct 2018
Microscopic examination of Giemsa-stained blood films remains a major form of diagnosis in malaria case management. More...
However, as with other visualization-based diagnoses, accuracy depends on individual technician performance, making standardization difficult and reliability poor.

Automated image recognition based on machine-learning, utilizing convolutional neural networks, offers potential to overcome these drawbacks. The application of digital image recognition to malaria microscopy, using artificial intelligence algorithms to replace or supplement the human factor in blood film interpretation, have been attempted, usually on thin films.

A team of scientists collaborating with Intellectual Ventures (Bellevue, WA, USA) conducted a cross-sectional, observational trial was conducted at two peripheral primary health facilities in Peru. They enrolled 700 participants whose age was between 5 and 75 years, and had a history of fever in the last three days or elevated temperature on admission. A finger prick blood sample was taken to create blood films for microscopy diagnosis, and additional drops of blood were spotted onto filter paper for subsequent quantitative polymerase chain reaction (qPCR) analysis. A prototype digital microscope device employing an algorithm based on machine-learning, the Autoscope, was assessed for its potential in malaria microscopy.

The investigators reported that at one clinic, sensitivity of Autoscope for diagnosing malaria was 72% and specificity was 85%. Microscopy performance was similar to Autoscope, with sensitivity 68% and specificity 100%. At one clinic, 85% of prepared slides had a minimum of 600 white blood cells (WBCs) imaged, thus meeting Autoscope’s design assumptions. At the second clinic, the sensitivity of Autoscope was 52% and specificity was 70%. Microscopy performance at this second clinic was 42% and specificity was 97%. Only 39% of slides from this clinic met Autoscope’s design assumptions regarding WBCs imaged.

The authors concluded that Autoscope’s diagnostic performance was on par with routine microscopy when slides had adequate blood volume to meet its design assumptions, as represented by results from one clinic. Autoscope’s diagnostic performance was poorer than routine microscopy on slides from the other clinic, which generated slides with lower blood volumes. The study was published on September 25, 2018, in the Malaria Journal.

Related Links:
Intellectual Ventures


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Automated Immunoassay Analyzer
SuperFlex™
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.